0
19. 12. 2025.
Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials
Take Home Message Real-world treatment of synchronous metastatic renal cell carcinoma with nivolumab + ipilimumab yields encouraging overall survival. Exceptional responders show excellent survival, even without deferred cytoreductive nephrectomy. Currently recruiting trials of deferred cytoreductive nephrectomy are likely to underestimate eventual survival in their control arms.